DCOY · XBRL financial data
Decoy Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (DCOY's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 5,233 | 1,840 | 0 | — | — | — |
| Research and development | 6,914 | 8,549 | 15,837 | 7,174 | 770 | 368 |
| General and administrative | 6,106 | 6,105 | 7,138 | 5,721 | 4,964 | 3,728 |
| Total operating expenses | 13,020 | 14,653 | 31,841 | 12,895 | 5,734 | 12,614 |
| Operating income (loss) | (7,786) | (12,813) | (31,841) | (12,895) | (5,734) | (12,614) |
| Income tax expense (benefit) | — | — | — | — | — | 0 |
| Net income (loss) | (7,352) | (12,768) | (31,608) | (12,543) | (5,576) | (12,518) |
| Earnings per share, basic‡ USD per share | (1,499.25) | (929.54) | (1,784.71) | (460.57) | (86.81) | (129.10) |
| Earnings per share, diluted‡ USD per share | (1,499.25) | (929.54) | (1,784.71) | (460.57) | (86.81) | (129.10) |
| Weighted average shares, basic‡ thousands of shares | 5 | 14 | 18 | 27 | 64 | 97 |
| Weighted average shares, diluted‡ thousands of shares | 5 | 14 | 18 | 27 | 64 | 97 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (October 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-8 stock split (June 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.992503748125937 stock split (August 2025); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (DCOY's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11,119 | 29,214 | 12,106 | 5,900 | 2,435 | 10,710 |
| Prepaid and other current assets | 822 | 949 | 803 | 620 | 553 | 275 |
| Total current assets | 15,797 | 30,164 | 14,520 | 6,520 | 2,988 | 10,985 |
| Property and equipment, net | 23 | 8 | — | — | 0 | 41 |
| Goodwill | 8,866 | 8,866 | 0 | — | — | — |
| Total assets | 24,932 | 40,834 | 14,651 | 6,587 | 3,023 | 11,057 |
| Accounts payable | 1,854 | 1,543 | 2,858 | 603 | 937 | 941 |
| Total current liabilities | — | — | — | — | 1,511 | 5,168 |
| Total liabilities | 2,773 | 2,111 | 4,266 | 1,299 | 1,511 | 5,168 |
| Accumulated deficit | (19,429) | (32,197) | (63,805) | (76,348) | (81,924) | (94,442) |
| Total stockholders' equity | 22,159 | 38,723 | 10,385 | 5,287 | 1,512 | 5,889 |
| Total liabilities and equity | 24,932 | 40,834 | 14,651 | 6,587 | 3,023 | 11,057 |
| Common shares outstanding (cover page)‡ thousands of shares | 15 | 16 | 21 | 36 | 116 | 532 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (October 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-8 stock split (June 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.992503748125937 stock split (August 2025); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (DCOY's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (7,352) | (12,768) | (31,608) | (12,543) | (5,576) | (12,518) |
| Stock-based compensation | 319 | 559 | 797 | 525 | 274 | 219 |
| Depreciation and amortization | 18 | 19 | 7 | 10 | 4 | 7 |
| Net cash from operating activities | (10,311) | (10,200) | (17,595) | (12,846) | (4,525) | (4,827) |
| Purchases of property and equipment | 3 | 0 | — | — | — | — |
| Net cash from investing activities | (3) | 0 | (1,500) | 0 | 0 | 765 |
| Dividends paid | 0 | — | — | — | — | — |
| Net cash from financing activities | 17,694 | 28,296 | 1,987 | 6,640 | 1,060 | 12,338 |
| Net change in cash | 7,380 | 18,096 | (17,108) | (6,207) | (3,465) | 8,275 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Decoy Therapeutics | 8,289 | 228 | (2,652)* | 655,185 | 3.1 quarters | 10-QJun 30, 2026 |
| Scorpius Holdings | 582 | not reported | (2,917)* | 61.1M | 0.2 quarters | 10-QSep 30, 2025 |
| Nomad Power Solutions | 12,670 | not reported | (1,612)* | 16.1M | 7.9 quarters | 10-QJun 30, 2026 |
| Clearside Biomedical | 6,801 | 201 | (5,480)* | 5.2M | 1.2 quarters | 10-QSep 30, 2025 |
| ProtoKinetix | 1.1 | not reported | 0.6* | 411.6M | — | 10-KDec 31, 2025 |
| Galera Therapeutics | 5,500 | not reported | (875) | 160.4M | 6.3 quarters | 10-QMar 31, 2026 |
| Cannapharmarx | 0.6 | 276 | (127)* | 708.7M | 0.0 quarters | 10-QJun 30, 2026 |
| Propanc Biopharma | 832 | not reported | (1,602)* | 6.3M | 0.5 quarters | 10-KJun 30, 2026 |
| Agentix | 0 | not reported | (26) | 40.1M | 0.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.